Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative

Taysha Gene Therapies (TSHA) drew fresh attention after early phase 1/2 REVEAL data for Rett syndrome showed all ten TSHA-102 recipients gained or regained at least one developmental milestone.

The early Rett data has arrived after a volatile run in Taysha Gene Therapies’ shares. The stock is up 8.84% on a 1-day share price return and 10.06% on a 7-day share price return, yet still down 21.51% on a 30-day share price return and 24.95% year to date. The total shareholder return shows a 23.50% decline over 1 year but a 75.11% gain over 3 years, pointing to long term holders sitting on gains even as shorter term momentum had faded before this latest move.

Spot opportunities around Taysha Gene Therapies by scanning a hand-picked 33 healthcare AI stocks that could benefit if neurology and gene therapy sentiment continues to build.

Bulls point to Taysha Gene Therapies’ early Rett data and long term total return, while bears focus on recent share price declines and ongoing losses. Which story does the current valuation support?

Most Popular Narrative: 69% Undervalued

Taysha Gene Therapies closed at $3.94, while the most followed valuation storyline pegs fair value at $12.85. This creates a wide gap that puts the Rett data and trial path under a bright spotlight.

Progress in the clinical development of TSHA-102, particularly moving towards the pivotal phase of the REVEAL trials with promising safety and efficacy data, could enhance investor confidence and potentially lead to future revenue growth once regulatory approval is achieved.

See why 13 investors see Taysha Gene Therapies as 69% undervalued.

This widely followed narrative applies a 7.22% discount rate and assumes revenue growth of about 214.8% a year, plus a future profit margin in line with the wider US biotech sector. It also leans on a very high implied future P/E of about 120x, which incorporates a substantial degree of anticipated success for TSHA-102 and the broader pipeline.

The same storyline recognises the execution risks. It flags the need for clean regulatory reviews, longer term safety data, competition in Rett syndrome and the reality that Taysha Gene Therapies is still loss making today, with earnings modeled to improve sharply over time rather than already in place.

For investors, the key question is whether those inputs feel realistic. The current share price reflects all the near term dilution, recent underperformance versus the US biotech industry and the fact that TSHA-102 remains in clinical development. The narrative fair value reflects a scenario in which the pivotal REVEAL trial, regulatory reviews and eventual commercialization proceed broadly in line with these optimistic assumptions.

Result: Fair Value of $12.85 (UNDERVALUED)

Still, the whole Taysha Gene Therapies narrative relies heavily on TSHA-102 trial success and timely FDA decisions, so any clinical or regulatory setback could quickly flip the script.

Find out about the key risks to this Taysha Gene Therapies narrative.

Another View: Taysha Gene Therapies Looks Expensive On P/B

Taysha Gene Therapies screens as undervalued on fair value models, yet its P/B of 3.3x is richer than the US biotech group at 1.8x and even slightly above direct peers at 3.2x. That richer multiple raises a simple question: Is the discount story already partly baked into the price?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Plenty in this Taysha Gene Therapies story leans optimistic, yet the risks are clear enough that you should move fast and test the numbers yourself. To see both sides of the ledger in one place, review the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Taysha Gene Therapies?

If Taysha Gene Therapies has your attention, do not stop with a single ticker. Broaden your watchlist so you are not relying on one outcome.

• Target resilient opportunities by scanning a 32 resilient stocks with low risk scores that filters for businesses with lower risk scores and steadier profiles than most high beta biotech names.
• Hunt for value by checking a 20 high quality undiscovered gems focused on strong fundamentals where market attention has not fully caught up yet.
• Strengthen the defensive side of your portfolio through a list of solid balance sheet and fundamentals (25 results) that highlights companies built on robust financial footing rather than fragile capital structures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com